Early signs CAR NKs could compete with CAR Ts in heme cancers

CAR NK cells could give CAR Ts a run for their money if early efficacy signals hold up

Early clinical data from CAR NK cells have started to roll in, and hint the modality could compete with CAR T cells on efficacy. Built into CAR NK cells are the benefits of off-the-shelf manufacturing and fewer safety risks.

Though the data come from only 11 patients, a study from University of Texas MD Anderson Cancer Center has found an efficacy signal for a CD19-targeted CAR NK cell therapy that is in line with marketed CAR T cells against the same target.

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502;

Read the full 851 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE